Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
20 September 2024
What similarly acting projects are still unpartnered?
2 June 2024
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
1 June 2024
Meanwhile, Lilly gets in on the next-gen KRAS action.
31 May 2024
Gilead came out swinging in second-line lung cancer, but it might have just whiffed.
31 May 2024
But will the FDA accept the surrogate endpoint used in ASC4First?
31 May 2024
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
31 May 2024
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
Recent Quick take
- 29 November 2023
- 28 November 2023
- 21 November 2023
- 21 November 2023
- 17 November 2023
- 17 November 2023
- 16 November 2023
- 16 November 2023
- 14 November 2023
- 13 November 2023